Compound sulfamethoxazole powder for children

1. Pharmacology This product is a sulfonamide antibacterial drug, a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP). It has good antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Proteus, Morganella, Shigella and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae. In particular, the antibacterial effect on Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus is significantly enhanced compared with SMZ alone. In addition, it also has good antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, protozoa, and Toxoplasma in vitro. The mechanism of action of this product is: SMZ acts on the action of dihydrofolate reductase, and the combination of the two can double-block the folic acid metabolism of bacteria. The synergistic antibacterial effect of this product is enhanced compared with a single drug, and the number of drug-resistant strains is reduced. However, in recent years, bacterial resistance to this drug has also been on the rise. 2. Toxicological animal experiments have found that long-term high-dose use of this drug can cause bone marrow suppression, leukopenia, and thrombocytopenia.

Chemical name: Sulfamethoxazole Molecular weight: C10H11N3O3S

This product is white or off-white granules with sweet taste.

Used for respiratory tract, intestinal and urinary tract infections in children.

Oral administration. 3 months to 1 year old: 1/3-1/2 bag at a time; 1-5 years old: 1 bag at a time; 5-8 years old: 1.5-2 bags at a time. Once a day or as directed by a doctor. Take with warm water.

1. Allergic reactions are common and may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and epidermolysis bullosa atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Newborns have imperfect liver function and need to handle bilirubin.

1. It is contraindicated for those who are allergic to SMZ and TMP. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, it is contraindicated for patients with this disease. 3. It is contraindicated for infants under 3 months old. 4. It is contraindicated for those with severe liver and kidney damage.

Precautions for children: This product is contraindicated for infants under 2 months old. Precautions for pregnancy and lactation: This product is contraindicated for pregnant and lactating women. Precautions for the elderly: Not yet clear.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic to each other. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or adverse reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. The combined use with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. Such as leukopenia, thrombocytopenia, etc. If there is an indication for combined use, possible adverse reactions should be closely observed.

Keep sealed.

Sulfadimethoxazole 0.1 g, trimethoprim 20 mg, sodium bicarbonate 0.1 g

24 months

Harbin Pharmaceutical Group Sanjing Children's Pharmacy (Co., Ltd.)

• Founded in:

  2005-01-03

• Address:

  No. 6, Sanjing Road, Sunwu County High-tech Park, Heihe City, Heilongjiang Province

• Tax NO.:

  9123112476270950X9

• Registered Funds:

  9.0779 million yuan

• Email:

  Log in to view